Flu places a significant burden on the health and economy of the United States1-3
In children ≤17 years of age, the impact of flu remains significant1,4
Annual CDC flu vaccination goals have not been reached
The CDC’s Healthy People 2030 objective for annual flu vaccination rate in children ages 6 months-17 years is 70%5
Approximately 36.2% of children in these age groups went unvaccinated6
2019-2020 flu vaccine estimated coverage rates for children by age group7
Additional options for influenza vaccination of children, including use of noninjectable vaccines, may help improve coverage8
The CDC states that overall vaccination coverage remains suboptimal, particularly in adults 18-64 years of age6
2019-2020 flu vaccination estimated coverage rates for adults by age group9
CDC recommends annual flu vaccination for everyone 6 months and older with any licensed, age-appropriate flu vaccine (IIV, RIV4, or LAIV4), with no preference expressed for any one vaccine over another.10
CDC=Centers for Disease Control and Prevention; IIV=inactivated influenza vaccine; LAIV4=quadrivalent live attenuated influenza vaccine; RIV4=quadrivalent recombinant influenza vaccine.
FLUMIST QUADRIVALENT is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUMIST QUADRIVALENT is for intranasal administration only.
You may report side effects related to AstraZeneca products by clicking here.